968
Participants
Start Date
December 31, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
November 30, 2012
Single-Dose IV Oritavancin Diphosphate
Oritavancin was administered as a single IV dose.
IV Vancomycin
Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
Placebo
Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Sharp Chula Vista Medical Center, Chula Vista
Lead Sponsor
Melinta Therapeutics, Inc.
INDUSTRY